These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25239934)

  • 1. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
    Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
    Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
    Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
    Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
    J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
    Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
    J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
    Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
    Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
    Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
    Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an Fn14 agonistic antibody as an anti-tumor agent.
    Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
    MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.
    Cao Y; Mohamedali KA; Marks JW; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2013 Jun; 12(6):979-91. PubMed ID: 23493312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.
    Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H
    Front Immunol; 2023; 14():1194610. PubMed ID: 37545514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
    Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
    Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
    Aronin A; Amsili S; Prigozhina TB; Tzdaka K; Rachmilewitz J; Shani N; Tykocinski ML; Dranitzki Elhalel M
    PLoS One; 2013; 8(10):e77050. PubMed ID: 24130833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
    Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
    J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
    Nakayama M; Ishidoh K; Kojima Y; Harada N; Kominami E; Okumura K; Yagita H
    J Immunol; 2003 Jan; 170(1):341-8. PubMed ID: 12496418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
    Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
    J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TWEAK-Fn14 system as a potential drug target.
    Wajant H
    Br J Pharmacol; 2013 Oct; 170(4):748-64. PubMed ID: 23957828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.
    Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE
    Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.